News
Public · Published
AARTIDRUGS: Q2 consolidated PAT reached ₹8,277 lakh as revenue rose to ₹82,624 lakh
Aarti Drugs reported consolidated Q2 revenue of ₹82,624 lakh and profit after tax of ₹8,277 lakh, with H1 profit after tax at ₹13,290 lakh. A ₹209 lakh write-off on capital work in progress was recorded, and one foreign subsidiary reported a loss.
Published:
Updated:
What happened
Aarti Drugs reported consolidated Q2 revenue of ₹82,624 lakh and profit after tax of ₹8,277 lakh, with H1 profit after tax at ₹13,290 lakh. A ₹209 lakh write-off on capital work in progress was recorded, and one foreign subsidiary reported a loss.
Confirmed
Global impact / market context
Profit after tax, which means the money left after all costs and taxes, shows the company's earnings. The write-off, meaning a reduction in the value of unfinished project spending, and the foreign subsidiary's loss show that some parts of the business are not yet adding to profit.
Analyst inference
Investors looking at drug makers often compare revenue growth with profits to see if costs are controlled. Here revenue of ₹82,624 lakh produced profit of ₹8,277 lakh, a modest share. The write-off and an overseas loss may lead investors to check whether capital spending is earning returns.
Analyst inference
What to watch
- Watch for further details on the ₹209 lakh write-off of capital work in progress, which means money spent on unfinished projects that is being written down. Confirmed
- A possible focus is whether management explains the foreign subsidiary's loss and sets out any plan to restore profitability at that unit. Proposed
- Investors may compare future quarterly revenue and profit to see if the cost pressure shown by lower profit relative to revenue continues. Analyst inference
Evidence
- Original source link unavailable